ReproCELL Incorporated (4978) Q1 2026 earnings summary

Executive summary

• Revenue for Q1 FY2026 was ¥475 million, a 23.2% decrease year-over-year; operating loss widened to ¥291 million from ¥115 million loss last year.

• Net loss attributable to shareholders was ¥304 million, compared to ¥75 million loss in the same quarter last year.

• Both core segments—Research Support and Medical—reported lower sales and increased losses, reflecting ongoing R&D and commercialization investments.

Financial highlights

• Gross profit for Q1 FY2026 was ¥194 million, down from ¥328 million year-over-year.

• SG&A expenses totaled ¥485 million, up from ¥443 million in the prior year.

• Total assets at quarter-end were ¥9,250 million, with net assets of ¥8,659 million and an equity ratio of 91.5%.

• Cash and deposits stood at ¥2,700 million, with marketable securities at ¥2,020 million.

Outlook and guidance

• Full-year FY2026 guidance maintained: revenue ¥3,037 million (+2.0% YoY), operating loss ¥268 million, net loss ¥75 million, EPS of -¥0.79.

• No change to previously announced forecasts; management highlights ongoing risks and uncertainties in achieving targets.